Operator: Thank you. Our next question comes from Mara Goldstein with Mizuho. Your line is open.
Mara Goldstein: Great. Thanks so much for taking the question. Just, I have a question on FT819 and not so much on 819, but really kind of the state of the world right now. And given what we are seeing from data and registration, with respect to bispecifics, and how you think about advancing 819. And then just on FT522, can you talk a little bit about what the €“ with rate limiting issues that are there for getting €“ for initiating an autoimmune program?
Scott Wolchko: So, with 819 to begin with, look, it’s the first iPSC derived for T-cells. I think it’s really important for us to advance that product candidate and understand its potential, are we truly making iPSC derived CAR T-cells, where does the activity level look like. Obviously, we have a very nimble and versatile platform, which we can improve upon shortcomings, whether that be for hematologic malignancies, or solid tumors. So, understanding the activity level of 819, I think it is really important. That said, like I said, I absolutely believe that there will continue to be room for efficacious CD19 targeted therapies, absolutely. Even in the phase of engagers, I mean we don’t fully appreciate the sequence of events, or sequencing of treatments, for instance, that will exist in the lymphoma space.
We may find that there is already data coming out in other areas, that bispecific engagers, when delivered aggressively into progression, CAR is for instance, and exhaustion on the T-cell compartment over time. That may not bode well for an autologous CAR T-cell therapy, and off the shelf T-cell therapy may be required for those patients. We also know for instance that and we have seen as you know, I mean most of the patients we treated in our Phase 1 study are actually post CAR T-cell therapy. And we certainly have looked at those patients that baseline CD19 expression. And we have seen responses, down line of patients that have been previously treated with CAR T-cell therapy. So, I continue to believe that a safe and effective off the shelf CD19 targeted therapy will absolutely have its place.
And we need to understand what the potential for FT819 is in that context, as well as inform the development of our platform and other product candidates, so definitely committed to 819 and that understanding. As it relates to 522, look our first commitment with FT522 is to file an IND in the space of B-cell lymphoma and combined with rituximab. I do not believe we will need to wait for significant clinical data in oncology to move into autoimmunity. And so from our perspective, it may be a pathway where we treated a couple of patients, established safety of the novel ADR receptor and its ability to function and then move into autoimmune.
Operator: Thank you.
Scott Wolchko: I think there just to finish, I think there is a unique opportunity in autoimmunity with FT522. I think FT522 could provide three axes of attack essentially against the pathogenesis, we can absolutely target CD19. So, keep in mind 522 because it has the CD38 knockout, can be combined with daratumumab in order to target plasma cells. And then the 4-1BB ADR technology is actually really unique when it comes to the potential for autoimmunity, because it can target, it will target and it can actually eliminate alloreactive and T helper cells. So, we think there is potentially a really unique three-pronged attack with the FT522 products in autoimmunity.
Operator: Thank you. Our next question comes from Matthew Biegler with Oppenheimer. Your line is open.
Matthew Biegler: Oh, hey guys. Scott, any plans on disclosing the remaining 596 and/or 516 data because I think you mentioned in the past that you thought the data were either compelling or competitive? So, just kind of want to get your thoughts on that. Thanks.
